Enbrel Maxing Out: Wyeth Sees Sales At Top End Of Forecast

Wyeth is "more confident than ever" that Enbrel will be "category leader" for TNF inhibitors, firm says. Enbrel on track for about $1.8 bil. in revenues this year.